ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers
Tromsø, Norway, December 9, 2024 – ArcticZymes Technologies (OSE:AZT) introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.The new SAN HQ ELISA SensoPlus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as